“Dr. Greenberg is an extraordinary physician-scientist whose pioneering research in cancer immunobiology and immunotherapy has contributed significantly to our understanding of the underlying responses of T cells to pathogenic viral infections and tumors. His important work has contributed greatly to improved patient outcomes and cures for certain late-stage melanomas and leukemias, and the advancement of cell therapies as a treatment modality,” said Margaret Foti, PhD, MD (hc), chief executive officer of the AACR. “We are deeply grateful for his exemplary service, and the AACR and its members will benefit enormously from his vision, scientific expertise, and commitment to our mission of preventing and curing all cancers. We congratulate him on being elected as the AACR’s 2022-23 President-Elect and 2023-24 President.”

Greenberg has been an AACR member since 2015 and was elected to the Fellows of the AACR Academy in 2019. He previously served on the AACR’s Finance and Audit Committee (2019-2022) and the AACR’s Board of Directors (2017-2020). Greenberg was the vice chair of the Annual Meeting program committee (2019-2020) and a member of the Annual Meeting education committee (2015-2016). Further, he was a member of the AACR’s Continuing Medical Education committee (2014-2017) and member (2015) and co-chair (2016) of the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference scientific committee. From 2012 to 2014, he was a member of the AACR-CRI Lloyd J. Old Award in Cancer Immunology selection committee. Greenberg is also a member of the AACR’s Cancer Immunology Working Group.


Greenberg serves as co-editor-in-chief of the AACR journal Cancer Immunology Research, where he was previously senior editor (2012-2015). From 1994-1997, Greenberg served on the editorial board for the AACR journal Clinical Cancer Research. He was also a member of the steering committee for the 2017 edition of the AACR Cancer Progress Report.

Greenberg was a member of the Stand Up To Cancer (SU2C)-Cancer Research Institute Cancer Immunology Dream Team and is currently a member of the SU2C-Lustgarten Foundation (LF) Pancreatic Cancer Dream Team. He was a reviewer of the SU2C-LF CAR T Research Team (2017-2020), the SU2C-Farrah Fawcett Foundation Human Papillomavirus Research Team (2016-2020), and the SU2C-LF Pancreatic Cancer Research Team (2014-2017). The AACR is the Scientific Partner of Stand Up To Cancer.

Greenberg has received numerous honors and awards throughout his remarkable career, including the Precision Medicine World Conference Luminary Award (2020), American Society of Hematology E. Donnall Thomas Lecture and Prize (2019), Seattle Business Magazine Gold Award as Leader in Health Care for Achievements in Medical Research (2018), Society for Immunotherapy of Cancer Richard Smalley Memorial Award (2018), Cancer Research Institute’s William B. Coley Award for Distinguished Research in Tumor Immunology (2011), International Society for Immunotherapy of Cancer Team Science Award for Career Achievements (2010), and the NIH MERIT Award (1991-1997, and 1997-2007). In addition to being a Fellow of the AACR Academy, Greenberg was elected to the Society for Immunotherapy of Cancer Inaugural Class of Fellows of the Academy of Immuno-Oncology (2021) and is a Distinguished Fellow of the American Association of Immunologists (2019), Fellow of the American College of Physicians (2008), Fellow of the American Association for the Advancement of Science (2007), and elected Member of the American Society of Clinical Investigation and the Association of American Physicians. Greenberg received his doctoral degree from the State University of New York, Downstate Medical Center in 1971. He was a postdoctoral research fellow at the University of California, San Diego from 1974 to 1976, and a senior fellow in the Division of Oncology at the University of Washington School of Medicine and the Fred Hutchinson Cancer Research Center from 1976 to 1978.

More People on the Move